Two-drug combo for stomach cancer with belly spread
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs, nab-paclitaxel and cadonilimab, as a second treatment for advanced stomach cancer that has spread to the belly lining. It may be an option if you haven't had any prior cancer therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have stomach or GE junction cancer that has spread to the lining of the belly (confirmed by a biopsy).
- You cannot have had any previous cancer treatment for this condition.
- You need to be in reasonably good health (able to care for yourself and do daily activities).
- You must not have serious heart, lung, or autoimmune diseases, or active infections like hepatitis B or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new chemotherapy combination for patients with advanced stomach cancer that has worsened after initial treatment. It aims to find a better second-line option using a drug called nab-paclitaxel.
This trial tests a new immunotherapy drug called cadonilimab combined with chemotherapy before surgery for stomach or gastroesophageal junction cancer. The goal is to shrink the tumor and improve outcomes for patients who are candidates for surgery.
This trial tests a three-drug combination (anlotinib, TQB2450, and nab-paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that is HER2-negative and has progressed after prior treatment with a CLDN18.2-targeted regimen. The goal is to see if this new combination can shrink tumors and help patients live longer.
This trial tests a new treatment plan for advanced stomach cancer using chemotherapy, anti-angiogenesis therapy (to cut off tumor blood supply), and immunotherapy (to help your immune system fight cancer). The goal is to see if this combination works better before surgery.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.